Wegovy 1mg: what to expect and what most people get wrong

The myth that 1mg is too low to work

One of the most common worries at this stage is that 1mg feels underwhelming. People read the 2.4mg figure, note they're sitting at less than half of it, and assume they're barely started. That framing misses how semaglutide's titration schedule works.

The step-up structure (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg) exists because GLP-1 medicines cause real gastrointestinal effects. Rushing to a higher dose before the body has adjusted doesn't produce faster weight loss; it produces more nausea, more discomfort, and often leads people to pause or stop treatment entirely. Each four-week window at a lower dose is doing something useful.

By the time most people reach 1mg, the appetite-reducing signal is noticeable. Portion sizes that felt normal a month ago feel like too much. The urge to snack in the evening tends to flatten. These are early signs the medicine is active, not a sign that you need to jump ahead. The full Wegovy overview covers how this mechanism builds across the schedule.

If you feel your progress is stalling, that conversation belongs with your prescriber, not with a decision to skip ahead unilaterally. Titration timing is a clinical call.

Side effects at 1mg: what tends to improve and what to watch

For most people, the 1mg period is more comfortable than the earlier steps. Nausea is typically at its worst in the first one to two weeks after a dose increase, then settles. By the time you've been at 1mg for a few weeks, many people find their digestive system has reached a working truce with semaglutide. That said, side effects don't disappear entirely, they shift.

Constipation can become more of a feature at this stage, partly because food intake has dropped and partly because gut motility slows with GLP-1 medicines. Staying well hydrated and keeping fibre intake up helps. Fatigue and mild headaches are reported less often at 1mg than at the initial doses, though they still occur. Reflux and burping are common, especially if eating habits haven't adjusted to smaller, slower meals.

The NHS medicines page for semaglutide lists the full side-effect profile with clear guidance on which symptoms warrant a call to your prescriber. Severe, persistent stomach pain that radiates to the back is not a dose-adjustment side effect, that needs prompt medical attention. The same applies to any signs of an allergic reaction.

A quick habit worth building: before each weekly injection, take 30 seconds to check the pen is clear and colourless. Cloudiness or visible particles are a reason not to use that dose and to contact your pharmacy.

What progress looks like, and what to track

Weight change at 1mg varies widely. Some people see a visible drop in this period; others plateau briefly before the next dose increase moves things forward. Both patterns are normal. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose, that cumulative result includes weeks spent at every step, including 1mg. No single dose stage tells the full story.

What matters more than the number on the scale right now is how your eating patterns are changing. Are you stopping meals earlier? Finding high-calorie foods less appealing? These behavioural shifts, driven by semaglutide's effect on appetite signals, are the mechanism through which the eventual weight loss compounds. Tracking them is more useful than weighing daily.

If you're approaching the step up, our guide to what to expect when increasing your Wegovy dose is worth reading before your next review so you feel prepared. And if you're still at an earlier point, the first-dose guide is a practical starting point.

Staying at 1mg longer, or moving up: a prescriber's decision

The standard schedule moves from 1mg to 1.7mg after approximately four weeks. But standard is not universal. If tolerability has been difficult (persistent nausea, significant fatigue, disrupted daily life) it is entirely reasonable for a prescriber to recommend a longer stay at 1mg. This isn't a setback. It's the medicine being used safely.

Equally, a dose increase is not automatic. At each review, a prescriber looks at how well the current dose is tolerated, what progress has been made, and whether there are any reasons to pause. If you're approaching the decision about moving to 1mg to 1.7mg, understanding what that step typically involves helps you go into the review with better questions.

The range of doses across the Wegovy schedule is covered clearly on the Wegovy doses page, including what each step is intended to do. For anyone exploring treatment for the first time, weight-loss treatment options outlines the broader landscape.

If you're not yet on treatment and want a clinical assessment, you can check your eligibility with our prescribers, the consultation is free, and every application is reviewed by a GPhC-registered Independent Prescriber the same day it's submitted.